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A B S T R A C T
One of the most challenging complications in trauma surgery is infection after fracture ﬁxation (IAFF).
IAFF may result in permanent functional loss or even amputation of the affected limb in patients who
may otherwise be expected to achieve complete, uneventful healing. Over the past decades, the problem
of implant related bone infections has garnered increasing attention both in the clinical as well as
preclinical arenas; however this has primarily been focused upon prosthetic joint infection (PJI), rather
than on IAFF. Although IAFF shares many similarities with PJI, there are numerous critical differences in
many facets including prevention, diagnosis and treatment. Admittedly, extrapolating data from PJI
research to IAFF has been of value to the trauma surgeon, but we should also be aware of the unique
challenges posed by IAFF that may not be accounted for in the PJI literature.
This review summarizes the clinical approaches towards the diagnosis and treatment of IAFF with an
emphasis on the unique aspects of fracture care that distinguish IAFF from PJI. Finally, recent
developments in anti-infective technologies that may be particularly suitable or applicable for trauma
patients in the future will be brieﬂy discussed.
ã 2016 Elsevier Ltd. All rights reserved.
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The operative ﬁxation of skeletal fractures can be highly
complex due to the unpredictable nature of the bone damage, the
multitude of concomitant injuries that may need to be considered
and the frequency of life-threatening situations in emergency care.
One of the most feared and challenging complications in the
treatment of musculoskeletal trauma patients is infection after
fracture ﬁxation (IAFF), which can delay healing, lead to
permanent functional loss, or even amputation of the affected
limb.
Treating IAFF may also result in signiﬁcant socio-economic
costs and can result in protracted recovery periods for affected
patients [1]. Recent studies showed median costs per patient
double to over 108'000 USD per patient when infected [2] with
reported treatment success rates of only between 70 and 90% [3,4].
The incidence of IAFF has been tracked in numerous small-scale
studies, with values from the 1980's and 90's indicating that the
infection rate may range from as low as approximately 1% after
operative ﬁxation of closed low-energy fractures, to more than 30%
in complex open tibia fractures [5,6]. Over the past decades, it
appears that there has been a steady reduction in the overall
incidence of infection [7]. However, the question must be asked as
to whether or not we have reached a plateau on what can be
achieved by current protocols [8]. The persistence of the problem,
and the somewhat unsatisfactory treatment outcomes, suggests
that neither prophylaxis nor treatment of IAFF is completely
effective despite best practice, and further improvements should
be sought.
Much of the surgical and medical treatment concepts currently
applied to IAFF have been adopted from prosthetic joint infection
(PJI) treatment algorithms. Speciﬁc data, tailored towards the
musculoskeletal trauma patient, is comparatively scarce. IAFF and
PJI do indeed have similar clinical properties, however there are
important distinctions between the elective arthroplasty patient
and the trauma patient, both in terms of risk of infection at the
primary surgery, and in treatment options. Clearly, there is likely to
be signiﬁcant differences in the soft tissues overlying the surgical
site: the fracture patient may have signiﬁcant soft tissue damage or
compromised vasculature secondary to the trauma, which is less
common in elective arthroplasty patients. This vascular and soft
tissue damage can impair access of the host defences and antibiotic
therapy to the affected areas. Open fracture wounds are also
certainly contaminated with an unknown variety and abundance
of contaminating bacteria that are not present in elective patients.
Furthermore, trauma patients may also require repeated visits to
the OR for deﬁnitive ﬁxation, second look, or plastic surgery for soft
tissue ﬂaps, which are not routine in primary arthroplasty.
Amongst the most obvious technical differences in IAFF is thePlease cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019presence of a fracture and the need for biomechanical stability in
order for it to heal. Clinical guidelines highlight the fact that
construct stability is important not only for prevention, but also for
treatment of IAFF [9,10]. Furthermore, in contrast to PJI, fracture
ﬁxation devices may be removed after osseous healing and
therefore complete immediate eradication of infection is not
always the primary goal and suppressive antibiotic therapy may be
an option in advance of later implant removal when treatment
outcome and success is likely to be improved. Finally, identiﬁcation
of infecting pathogens may be possible by joint puncture prior to
surgical intervention in the case of PJI, however, biopsies are more
often taken intraoperatively for IAFF, which can delay or
complicate diagnosis of IAFF.
Preclinical research studies looking into the risk and progres-
sion of bone infection speciﬁcally in trauma-relevant models are
also scarce [11–13], and few speciﬁc innovations have been
translated from the academic arena and made available to the
musculoskeletal trauma surgeon [14–16]. In this review, we
summarize the preventative, diagnostic and therapeutic guidelines
for IAFF with an emphasis on the unique aspects of fracture care
that distinguish IAFF from PJI. Furthermore, we summarize the
latest preclinical and clinical research innovations regarding
prevention and treatment of IAFF.
Deﬁnition and classiﬁcation
Deﬁnition
Accurately estimating the impact of fracture related complica-
tions has been hampered by the lack of clear deﬁnitions for
complications such as nonunion or infection. To date, there are no
available standard criteria and a lack of consensus regarding the
deﬁnition of IAFF. This is in contrast to the situation for PJI, where a
deﬁnition is available [17]. The trauma literature often cites the
Centers for Disease Control (CDC)-guidelines for surgical site
infection (SSI). The CDC deﬁnition divides SSIs into superﬁcial,
deep incisional and organ/space [18]. Furthermore, osteomyelitis is
stated separately. As the fracture nor the implant taken into
account, the complexity of an infected traumatic fracture is not
completely covered by these guidelines. The problem becomes
clear when reviewing the clinical literature. Some studies have
cited the CDC-guidelines without a speciﬁc description of
osteomyelitis [19,20]; others use these guidelines but include
their own additional inclusion criteria such as purulent drainage or
other clinical signs [21]. Perhaps due to the lack of suitable
deﬁnitions for trauma patients, there are also authors who do not
deﬁne infection [22] and others who provide a unique custom-
made deﬁnition [23]. Interestingly, this issue was already
mentioned by Arens et al. in 1996 [24], wherein the authorster fracture ﬁxation: Current surgical and microbiological concepts,
Fig. 1. Pathophysiology, classiﬁcation and treatment algorithm of IAFF.
1 See Table 4: Factors favoring implant removal and exchange
2 Reconstruction can be carried out in a single step (with implant exchange) or in multiple stages; after resection of necrotic soft-tissue and bone a multidisciplinary approach
will often be required
3 Antibiotic therapy should be chosen in collaboration with an infectious disease specialist (especially in polymicrobial infections or proof of difﬁcult to treat pathogens)
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mentioned, the term ‘infection’ is not deﬁned’. A better understand-
ing and description of the deﬁnition of IAFF is therefore a needed
ﬁrst step towards improving scientiﬁc reporting and evaluation of
routine clinical data, as well as aid in the evaluation of novel
prevention and treatment strategies [25].
Classiﬁcation
Although there is a lack of clear deﬁnitions, there is a widely
accepted classiﬁcation scheme for IAFF [26,27]. Willeneger and
Roth classiﬁed IAFF in the 1980's according to the time of onset into
three groups: those with an early (less than 2 weeks), delayed (2–
10 weeks), and late onset (more than 10 weeks) infection [27]. This
classiﬁcation has been adopted widely and is important because it
has an inﬂuence on treatment decisions made by physicians [26].
Although infections with delayed and late manifestations may be
combined [26], a trisection of this classiﬁcation seems more
appropriate. The relative frequency of infections of each type is not
available from the published literature, but would represent an
interesting validation of the classiﬁcation scheme should such data
become available. In the following section, this classiﬁcation will
be discussed, with particular reference to onset of IAFF, bioﬁlm
formation and, importantly for the trauma surgeon, fracture-
healing status (Fig. 1).
Early infection (<2 weeks)
Early IAFFs are often a clinical diagnosis since the patient
generally presents with classic signs of infection (rubor, calor,
dolor, tumor and functio laesa), wound healing disturbances, largePlease cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019hematomas, and accompanying systemic signs of infection such as
fever and lethargy. Highly virulent organisms, like Staphylococcus
aureus, are frequent causative agents of early infection [26]. Within
this timeframe, it is commonly considered that the causative
bacteria may already have formed a bioﬁlm, although this bioﬁlm
may still be in an ‘immature’ phase.
With regard to bone involvement and healing, preclinical
models have shown that at one-week post-inoculation, the bone
does not show signs of osteomyelitis or osteolysis (Fig. 2), despite
the presence of bacteria. Furthermore, bone healing is in the
‘inﬂammatory or soft callus stage’ [28], and so there will be no
fracture stability at this early stage. As discussed later, these
pathophysiological conditions (active infection without radio-
graphic signs of fracture stability) have signiﬁcant treatment
consequences due to the importance of fracture healing for
successful treatment outcomes.
Delayed infection (2–10 weeks)
Patients with delayed infections can present with symptoms
consistent with either early or late infections. For example,
hematomas, which may be expected in earlier stages, may still
be present after 3 weeks, or alternatively, a ﬁstula can also present
itself after 9 weeks, which may be more often associated with late
infections.
There are several important distinctions from early infections.
Delayed infections are typically due to less virulent bacteria, such
as Staphylococcus epidermidis [26], and as the duration of infection
extends, bioﬁlms mature and become more resistant to antibiotic
therapy and host defenses.ter fracture ﬁxation: Current surgical and microbiological concepts,
Fig. 2. Histological sections revealing the time-dependent changes in an artiﬁcially contaminated (S. aureus) osteotomy of the rabbit humerus. Upper panel, from left to right
shows the changes in the soft tissues overlying an LCP from the early post-operative phase (left) where some early signs of inﬂammation are observed over the plate, to the
position at 4 weeks, (center) where signiﬁcant necrosis is observed. By ten weeks, the necrosis has resulted in a capsule formation surrounding the necrotic tissue adjacent to
the LCP. Bone involvement lags behind the soft tissue involvement, which at 1 week (lower panel, left) is non-existent. By four weeks (center), the bone is showing signs of
osteolysis and failure to heal, although this is more pronounced at ten weeks (right), at which time non-union is seen including sequestration of necrotic one fragments.
(Giemsa Eosin stained, upper panel scale bar 200 micrometers, lower panel, scale bar 1000 micrometers).
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normal bone healing takes up to 10 weeks [29], with a ‘hard callus
stage’ that is situated between 3 and 16 weeks [28,30]. In case of
infection, this changes signiﬁcantly. Experimental studies have
shown that S. epidermidis inoculation into a fracture gap in the rat
can lead to non-union rates of 83–100% at 8 weeks [31]. Bilgili et al.
could prove, in a similar approach, that IAFF was associated with
weaker callus formation [32]. These observations, in combination
with the fact that bacterial bone invasion and inﬂammation
(‘osteomyelitis’) often occur within 2–10 weeks (Fig. 2), explain
why treatment choices are often different compared to early onset
infections where fracture healing may not have commenced, and
bone involvement may still be minimal.
Late infection (>10 weeks)
Many patients with late infections can present with subtle
symptoms, compromised functionality and stress dependent pain,
localized swelling and erythema or a draining sinus tract, mostly
lacking systemic manifestation [33,34]. In patients presenting with
compromised functionality and stress dependent pain, infection
with low-virulence microorganisms should always be considered a
possible cause (a clinically silent infection) [33]. Late, as delayed,
IAFF is primarily caused by micro-organisms of low virulence like S.
epidermidis [26].
Compromised fracture healing is a frequent observation in late
infections and although bone healing may have taken place in
some cases, severe inﬂammation and osteolysis with osteomyelitis
lead to instability of the osteosynthesis (Fig. 2). Periosteal new
bone formation around the periphery of the infected area produces
an involucrum that further walls off the infection [35]. These
changes often necessitate extensive and repeated debridements,
resulting in bone defects.Please cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019Diagnosis
The diagnosis of IAFF is challenging and based on a combination
of various diagnostic criteria: past medical history, host physiology,
clinical presentation, laboratory tests, imaging modalities and
culturing of intraoperative tissue samples. Local signs of infection
should be considered an IAFF until proven otherwise. Signs such as
a draining ﬁstula from the implant or pus drainage are considered
deﬁnitive signs of infection.
Evaluation of host physiology
The detailed examination of patients with a suspected IAFF
includes a clinical assessment, and complete medical history, as
well as an evaluation of the host local and systemic risk factors.
High-risk injuries including open fractures with severe soft-tissue
damage, a previous history of infection or a compromised host
physiology [36]. Characteristics of compromised host physiology,
such as chronic immune suppression (diabetes, malignancy, severe
liver or renal disease, alcoholism), impairment of local vascularity
and soft-tissue integument or deﬁciency in wound healing, should
not only inﬂuence the risk assessment for infection, it should also
inﬂuence treatment concepts [37]. Therefore, treating surgeons
should be reluctant to perform complex reconstructive procedures
in patients where these high-risk host factors are identiﬁed
[33,38].
Laboratory examination
White blood cell count (WBC) with differential and neutrophil
count display low sensitivity and speciﬁcity for diagnosing IAFF
[26,39]. Persistent elevation or a secondary rise in C-reactive
protein (CRP) can be an indicator for IAFF [40,41].ter fracture ﬁxation: Current surgical and microbiological concepts,
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IAFF is mostly due to bacterial communities growing in
protected bioﬁlms on the foreign material and in necrotic bone
tissue [42]. These localized grouped bacteria are often metaboli-
cally quiescent, which makes them difﬁcult to identify and culture
[43,44]. Cultures taken from an open wound at the time of initial
fracture ﬁxation do not correlate with an eventual later infection
and should be avoided [45,46]. Similarly, swab cultures at the time
of revision surgery do not reliably represent the pathogens in the
bone [47,48] and are therefore not recommended. In case of
suspected infection, at least three bone biopsies should be taken
close to the implant and in regions of macroscopically perceived
infection such as necrotic bone tissue or non-unions [26]. If the
same microorganism is cultured in at least two separate biopsies, it
is believed to be relevant. In case of virulent species such as S.
aureus or E. coli, a single positive biopsy may already sufﬁciently
represent an infection [17]. If involvement of an adjacent joint is
suspected, joint ﬂuid for analysis (cell count, cultures) should be
aspirated. Whenever possible, antibiotics should be avoided for at
least 2 weeks before microbiological culturing, since this can
transform speciﬁc bacterial species into viable but non-culturable
forms [49] and cultures may therefore become falsely negative
[50]. There is still an on-going debate about the duration of culture
incubation: from 7 up to 14 days of incubation can be reasonable
[51,52], balancing the risk of missing a difﬁcult to culture pathogen
with the risk of culturing an irrelevant contaminant.
If implanted hardware is removed during surgery, these should
be sent to the microbiological laboratory for sonication and
cultivation of sonication ﬂuid, if possible. Sonication is believed to
detach the bioﬁlm-encased bacteria from the implant and disrupt
the bioﬁlms themselves, thereby rendering the bacteria amenable
for cultivation. This method has proved to increase the yield of
positive cultures, especially after pre-treatment with antibiotics
[53–56].
Although culturing is still believed to be the gold standard for
microbiologic assessment, molecular methods are increasingly
being added to identify difﬁcult to culture or non-culturable
bacteria. Especially after antibiotic pre-treatment, detecting
pathogens with polymerase chain reaction (PCR) has proven to
be a valuable complementation [57–59]. However, the high
resolution and sensitivity of PCR comes along with the risk of
false-positive results from contaminants [60,61]. Furthermore, it
commonly cannot distinguish between live or dead bacteria and
does not provide broad information about susceptibility to
antibiotics, except of the presence of speciﬁc resistance genes [62].
Histology
Routine diagnostics of IAFF may include histological analysis of
several tissue samples, that were taken intra-operatively from the
site of suspected infection and/or non-union [63]. The histological
examination allows differentiation between acute and chronic
infection, proof of necrotic bone and detection of malignancy and
delivers in combination with microbiological analysis important
clues on the presence of a bone infection [33].Table 1
Central aims of treating IAFF.
1. Fracture consolidation
2. Eradication of infection or in certain cases 
3. Healing of the soft-tissue envelope
4. Prevention of chronic osteomyelitis
5. Restoration of functionality
Please cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019Imaging
Serial radiographs are the ﬁrst method of choice in complica-
tions after fracture ﬁxation to gain a primary overview of the
anatomy and to judge fracture healing status, implant positioning,
possible implant failure, limb alignment and bone quality [64].
However, plain radiographs are not suitable to differentiate
between septic and aseptic changes in active infections [26,65].
In chronic infections, areas with a suspected bone infection may
display sequestration, cortical irregularities, bone resorption and
bone/callus formation [33,65]. For more precise planning of the
surgical procedure, computed tomography (CT) provides more
detail about bone architecture to evaluate fracture pattern, new
bone formation and necrotic bone as well as implant loosening and
delivers additional evidence for infection: cortical bone reaction,
presence of sequestration or intraosseous ﬁstula and abscess
formation in the adjacent soft-tissue [33,66,67].
Magnetic resonance imaging (MRI) is the method of choice to
evaluate soft-tissue involvement and gives additional information
about intramedullary infection manifestation [39]. However in
cases of IAFF, metal artefacts impair correct evaluation and scarring
or edema in postoperative/posttraumatic bone defects may mimic
an infection [68].
Nuclear imaging modalities are often included in the diagnostic
pathway of these type of infections [69,70]. Nuclear imaging is
using radioactive radiopharmaceuticals to visualize and trace
(patho-) physiological changes, such as fracture healing, bone re-
modelling and inﬂammatory response to an infection. The
combination of these functional imaging studies with morpholog-
ical imaging, such as CT in one device is called hybrid imaging
(SPECT/CT). It allows precise localization of the suspected infection
and facilitates the discrimination between bone and soft-tissue
infection [70]. Bone scintigraphy, usually performed with techne-
tium-99m-diphosphonates (99mTc) is positive for osteomyelitis in
the case of focal hyperaemia or hyperperfusion and focally
increased bone activity [70]. Since these physiological changes
are also involved in fracture healing, it cannot discriminate
between infection and posttraumatic bone formation. Therefore,
bone scintigraphy has limited value in the diagnosis of IAFF
[26,39,70]. WBC imaging, using in vitro labeled leucocytes is a
promising technique to identify bacterial infections, but is not
routinely available due to complex in vitro labeling [70]. 18F-
ﬂuoro-desoxy-glucose PET (FDG-PET), is very useful in musculo-
skeletal infections to visualize and precisely localize the infection
with a high sensitivity and speciﬁcity [70]. Its role in IAFF still
remains inconclusive and has to be determined.
Treatment
General considerations
The central aims of treating IAFF are shown in Table 1.
Remember that every case of IAFF is to be considered as a unique
case, since there is no standard procedure that can be routinely
applied to every patient.
In contrast to PJI, fracture ﬁxation devices can be removed after
healing has occurred, thereby removing the bioﬁlm and resultingsuppression of infection until fracture consolidation is achieved
ter fracture ﬁxation: Current surgical and microbiological concepts,
Table 2
Questions to tailor the appropriate treatment strategy.
1. Onset of symptoms (classiﬁcation): early–delayed–late onset of infection?
2. Fracture healed or stable callus formed?
3. Osteosynthetic construct: stable implant and satisfactory fracture
reduction?
4. Type of implant (e.g. plate, nail, external ﬁxation)?
5. Fracture localization (e.g. diaphyseal, articular)?
6. Condition of soft-tissue envelope?
7. Local and systemic host physiology?
8. History of infection at site of interest?
9. Difﬁcult to treat pathogen?a
a In general not available for the primary revision, since pre-operative pathogen
identiﬁcation is often not possible (in contrast to PJI, due to joint aspiration);
microbiology results should be taken into account as soon as available.
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eradication of infection is not always the primary goal. Suppressive
therapy with antibiotics can be an established alternative in
certain cases [3,26,71]. In order to tailor the appropriate treatment
strategy, a number of important questions should be considered
(Table 2) [1,26,39].
Taking these considerations into account, the above-mentioned
aims can be achieved by two main surgical principles:
I Irrigation, debridement and retention of the implant combined
with antibiotic therapy.
II Debridement, implant removal or exchange (one or multiple
stages) with accompanied antibiotic therapy.
In very rare cases, especially in compromised hosts with serious
infections, healing cannot be achieved and salvage procedures,
such as amputation or establishment of a continuous ﬁstula, may
be the only treatment alternatives.
Regardless of which of the two main principles was chosen, the
treating surgeon has to apply the above-mentioned diagnostic
tools (CRP, radiographic analysis, etc.) to develop a long-term
treatment concept as part of a multidisciplinary team. This
treatment concept encompasses debridement, fracture- and
soft-tissue management and antibiotic therapy (systemic/local).
Carefully considered debridement is the cornerstone of treatment
and involves the excision of necrotic and infected (bone- and soft-)
tissue, evaluation of the osteosynthetic construct (stability),
removal of foreign bodies (e.g. sequesters, broken screws, sutures)
and acquisition of multiple tissue samples for diagnostics [72].
Radical debridement should not be limited by concerns of creating
bone or soft-tissue defects [33], one must compare debridement to
‘Oncologic resections’. Leaving a high concentration of pathogens
(‘cancer cells’) in a speciﬁc surgical area, will lead to recurrence of
the disease. When multiple operative stages are planned, these
defects should be temporarily ﬁlled with a spacer (‘dead-space
management’). Finally, an adequate soft-tissue coverage is essen-
tial. This often means involvement of plastic surgeons in the
process, for e.g. free-ﬂaps.
Antibiotic treatment considerations
Systemic antibiotic therapy
In general, antibiotic therapy can either be curative or
suppressive. In the latter case, the antibiotics control the infection
until the fracture is healed and the implant can be removed [26].
Antibiotics should always be tailored to the recovered bacteria and
their antibiotic susceptibility pattern (see Table 3).
After surgical debridement, an initial intravenous therapy is
started to achieve a rapid reduction of the bacterial load at the site
of infection. After approximately 2 weeks of intravenous therapy, a
switch to oral therapy with good bioavailability is suggested (seePlease cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019Table 3) [73–75]. In case of treatment with aim of cure, the total
treatment duration is usually 6 weeks after removal of implants or
12 weeks if implants stay in place [26,72]. In case of treatment with
aim of suppression, duration of therapy is linked with the time for
the fracture to stabilize/heal and should commonly be continued
for 4–6 weeks after implant removal. This is particularly
recommended in infections with virulent bacteria such as S.
aureus or E. coli in order to prevent or treat chronic osteomyelitis.
When implants are retained, a curative treatment is generally only
effective with a bioﬁlm-active antibiotic, which has so far only
been shown for rifampicin against staphylococci [76–78] and for
quinolone against Gram-negative bacteria [79–81]. Importantly,
rifampicin must always be combined with a second antibiotic due
to otherwise rapid development of resistance. For the same reason
rifampicin should not be started before an initial bacterial load
reduction by surgery and antibiotic therapy has occurred, all drains
are drawn and the wound is dry [82,83]. For staphylococci,
quinolones such as ciproﬂoxacin or levoﬂoxacin are the best-
studied and effective oral antibiotic partners to rifampicin [76].
Other combinations have been successfully used in orthopedic
implant infections but are less widely studied (see options in
Table 3) [84]. If bacteria are resistant to the mentioned bioﬁlm-
active antibiotics, they are classiﬁed as difﬁcult to treat and
generally cannot be eradicated by the available alternative
antibiotics as long as the implants are retained [85]. In these
cases, the surgeon should strongly consider implant removal.
Local antibiotic therapy
Local application of antimicrobials at the site of infection
through different carriers has gained increasing attraction.
Especially in the light of impaired blood ﬂow to the site of
infection and necrotic bone tissue, the advantage of achieving very
high local concentration of antimicrobials with low systemic
exposure is compelling [87]. Furthermore, their carries can be an
important treatment option for ‘dead-space management’. Nowa-
days, the mostly used antimicrobials are gentamicin, tobramycin,
vancomycin and cephalosporins [88]. As a carrier, one can
differentiate between resorbable versus non-resorbable materials.
Commonly, an antibiotic loaded non-resorbable polymethylme-
thacrylate (PMMA) bone cement is applied, which can be
introduced as beads on a string or simultaneously be used for
mechanical stabilization as a rod or for temporary ﬁlling of large
bone defects [89]. Nevertheless, cement may also serve as an
additional surface for bacteria to attach to, particularly after
antibiotics have been eluted. This can promote ongoing infection or
even induce antibiotic resistance [90–93]. Another negative aspect
of PMMA is that it needs to be removed during follow-up surgery,
as it is non-resorbable. Furthermore, studies on the elution kinetics
have shown that less than 10% of incorporated antibiotics will
normally be released from PMMA [94]. Increasing the porosity of
the material or mixing e.g. vancomycin with tobramycin can
produce higher eluted doses [95,96].
Resorbable materials such as calcium sulfate, which can carry a
wider range of antibiotics than PMMA and do not necessarily need
re-surgery for removal, have shown good ﬁrst results [97–100]. As
a side effect, a serous ﬂuid pocket or prolonged wound secretion
can develop [101]. Other degradable materials are bioactive glass,
calcium phosphates and collagen implants. It needs to be stated
that for all these materials data from large clinical trials is lacking.
To date, there is no clear evidence of advantage of the addition
of local antibiotic to systemic therapy in randomized clinical trials
and no clear advantage of degradable versus non-degradable
materials in the treatment of IAFF [102–104]. Despite this, local
antibiotics seem to lower infection rates in open fractures [105].
The antibiotics generally exert low local and systemic toxicity
[106,107]. Nevertheless, there are rare case reports of acute renalter fracture ﬁxation: Current surgical and microbiological concepts,
Table 3
Antibiotic treatment according to the pathogen (adapted from Zimmerli et al. [86]).
Pathogen Antibiotic therapy Dose (normal renal function)
Staphylococcus spp. 2 weeks
Methicillin-susceptible Flucloxacillin plus 2 g every 6 h. iv.
Rifampicin 450 mg every 12 h iv./po.
Methicillin-resistant 2 weeks
Vancomycin or 15 mg/kg every 12 h iv.
Daptomycin plus 6–8 mg/kg every 24 h iv.
Rifampicin 450 mg every 12 h iv./po.
all Staphylococcus spp. followed by
Rifampicin plus 450 mg every 12 h po.
1st choice
Ciproﬂoxacin or 750 mg every 12 h po.
Levoﬂoxaxin or 500 mg every 12 h po.
2nd choice
Cotrimoxazole or 1 double strength tablet every 8 h po.
Fusidic acid or 500 mg every 8 h po.
3rd choice
Clindamycin or 600 mg every 8 h po.
Minocyclin or 100 mg every 12 h po.
Linezolid 600 mg every 12 h po.
Streptococcus spp.a 4 weeks
Penicillin G or 5 Mio IU every 6 h iv.
Ceftriaxon 2 g every 24 h iv.
followed by
Amoxicillin or 1000 mg every 8 h po.
Clindamycin 600 mg every 8 h po.
Enterococcus spp. whole therapyb
Penicillin-susceptible Amoxicillin or 2 g iv. every 6 h iv.
Penicillin G 5 Mio IU every 6 h iv.
Penicillin-resistant whole therapy
Vancomycin or 15 mg/kg every 12 h iv.
Daptomycin or 6–8 mg/kg every 24 h iv.
Linezolid 600 mg every 12 h iv./po.
Enterobacteriaceae 2 weeks
b-lactam antibiotic according to susceptibility iv.
followed by
Ciproﬂoxacin 750 mg every 12 h po.
Enterobacter spp. and Nonfermenters
(e.g. P. aeruginosa)
2–4 weeks
Cefepime or prolonged infusion (3 h):
Ceftazidimc or 1–2 g every 8 h iv.d
Meropenem 2 g every 8 h iv.
followed by 1–2 g every 8 h iv.d
Ciproﬂoxacin 750 mg every 12 h po.
Propionibacterium spp. 2–4 weeks
Penicillin G or 5 Mio IU every 6 h iv.
Ceftriaxone 2 g every 24 h iv.
followed by
Amoxicillin or 1000 mg every 8 h po.
Clindamycin 600 mg every 8 h po.
Gram-negative Anaerobes
(e.g. Bacteroides)
whole therapy
Metronidazol 500 mg every 8 h iv./po.
Mixed infections
(without methicillin-resistant S. aureus)
Individualized therapy according
to susceptibility
a Measuring minimal inhibitory concentration (MIC) for penicillin recommended.
b Iv.- therapy if curative intention, for suppressive therapy consider e.g. amoxicillin 750–1000 mg every 8 h po.
c No Ceftazidime for Enterobacter spp. (even if measured susceptible), alternative: Ertapenem 1 g every 24 h.
d In infections with Pseudomonas: high dosage recommended.
e If penicillin allergy Type I (anaphylactic): Clindamycin 600–900 mg every 8 h iv.
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tobramycin [109].
Exploring the effect of coating osteosynthetic materials with an
antimicrobial is a matter of ongoing research. Only few have made
it so far onto the market. Among these are a gentamicin-coated
intramedullary tibia nail [16,110] and silver-coated megaprosthe-
ses [111].Please cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019Stage-dependent surgical treatment considerations
Treatment of early infection
Colonization of hardware can occur intraoperatively, and
bioﬁlm formation may proceeds within days, with the implant
thus serving as the nidus for infection and complicating healing/
treatment [3,112–114]. In this early stage, bioﬁlm formation seems
in an immature stage, and fulminant osteomyelitis is often not yet
present [29,115]. Only in very rare clinical situations, such aster fracture ﬁxation: Current surgical and microbiological concepts,
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histological signs of inﬂammation of the bone/bone marrow) occur
in this timeframe. This is why retention of the fracture ﬁxation
device is common practice and treatment involves antibiotic
therapy and tissue debridement. Experimental studies in the rat
have shown that callus formation could be observed despite
retention of the implant [32]. Retaining an implant in early stages
is tempting because hardware removal would complicate the
management of an unhealed fracture, especially in complex
articular fractures. However, retention of the implant is only
reasonable if sufﬁcient irrigation and debridement of the implant/
surgical site can be carried out, if the osteosynthesis construct is
stable, and antibiotic therapy is appropriate [72,116]. The impor-
tance of implant stability was already outlined by earlier research
from Rittmann and Perren in experimental studies in sheep, which
showed the positive effects of stability on fracture healing in
infection [9]. Furthermore, stability has a much more profound
inﬂuence than that of the chosen implant material (i.e. different
metal alloys) [117,118]
In early infections, consolidation can be achieved despite the
presence of an infection, as long as the osteosynthesis construct
remains stable [9,119]. If stability is not granted and the implant
cannot be debrided properly, e.g. in intramedullary nails, hardware
exchange should be considered [36]. Debridement also includes
careful revision of hematomas, since they are a suitable growth
medium for bacteria [26]. Subsequently, a 12-week course of
antibiotic therapy with retained implants or up to 6 weeks after
implant removal should follow the debridement [26,78,120]. Since
debridement reduces the bacterial load and may clear an immature
bioﬁlm, additive systemic antibiotics will treat the remainder of
the infection. Once the fracture has healed, it is strongly
recommended to remove the implant to reduce the risk of a
recurrent infection [119]. Berkes et al. investigated osseous union
in patients who developed an infection within 6 weeks after the
operative fracture ﬁxation and that were treated with debride-
ment, antibiotics and hardware retention. Fracture healing could
only be achieved in 71% of the patients, whereas an open fracture
and the presence of an intramedullary nail were predictors for
treatment failure [3]. Rightmire et al. performed a similar approach
in infections within 16 weeks after osteosynthesis and reported
successful union in 68%, although in 38% of the patients with
successful bone healing, hardware had to be removed for
persistent infection after union and therefore only 49% of the
original study group achieved healing and was free of infection
after six months [119]. These ﬁndings support the fact that the
approach of debridement and retention is only promising in an
early time frame after fracture ﬁxation to achieve union and long
term absence of infection.
In the majority of early infections retention and antibiotic
therapy is the best option [26], but there are indications where
exchanging the implant should be taken into account [26,39,119].
The factors are listed in Table 4. These factors should be interpreted
as suggestions, rather than as deﬁnite decision criteria.Table 4
Factors favoring implant removal and exchange.
1. Nail osteosynthesisa
2. Unstable osteosynthesis or insuf
3. Compromised soft-tissue envelop
4. Compromised host physiology (a
5. Difﬁcult to treat pathogenb
a Exchange/removal strongly recommended.
b In general not available for primary revision since pre-op
in PJI by joint aspiration), if in retention of implant was cho
difﬁcult to treat pathogen, removal of the implant should s
Please cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019Treatment of delayed infection
Delayed infections, ranging from 3 to 10 weeks are a grey area in
which decision making regarding the right treatment option is
more difﬁcult than in early or late onset infections. It is important
to understand that the classiﬁcation we use (Fig. 1) is a continuum,
which means that in the early stages of this phase, implant
retention could still be considered, whilst at the later stages, this
would be more clearly contraindicated.
In the presence of above-mentioned criteria (Table 4), and with
increasing duration of symptoms or delay in diagnosis, the decision
should tend towards implant exchange. As explained above, the
bioﬁlm develops (matures) over time and signs of osteomyelitis are
increasingly observed (Fig. 2), which means that treating these
types of infection often demands for radical debridement and
implant exchange. An important consideration in delayed infection
is the evaluation of fracture consolidation by imaging studies and
during surgery. If callus formation is visible and bone healing has
progressed sufﬁciently to provide stability, debridement and
implant removal can be the best choice.
The main principles of debridement and implant removal/
exchange in one or multiple stages are outlined in the subsection
“Late infections”.
Treatment of late infection
In the following section we summarize three different
scenarios: clinically suspected infection with full bone consolida-
tion, clinically suspected infection without full bone consolidation,
and non-union lacking clinical signs of infection. The ﬁrst two
scenarios will be discussed together.
Clinically suspected infection with and without full consolidation
As mentioned previously this classiﬁcation of IAFF is a
continuum (Fig. 1). Although this means that there is no red line
separating late and delayed infections, it has to be taken into
account that after 10 weeks (Fig. 1), inﬂammation, ﬁbrous
encapsulation and osteolysis often lead to instability of the
osteosynthesic construct, potentially resulting in delayed or non-
union [29]. Furthermore, ﬁbrous encapsulation of the infected area
acts as a barrier around sequesters and devitalized bone.
Clinically suspected late infection necessitates an extensive
debridement with possible creation of bone and soft-tissue
defects. The surgical treatment concept therefore has to include
a multidisciplinary approach (trauma and plastic surgeon). Staged
procedures may often be required, depending upon the extent of
infection, the degree of stability, and the condition of the patient
(host physiology).
The most important considerations in late infections with, and
without, consolidation of the fracture are: removal of the
remaining fracture ﬁxation devices/foreign bodies; radical de-
bridement of all involved bone (sequesters) and soft tissue; long-
term antimicrobial therapy (normally 6 weeks of antibiotics and up
to 12 weeks if a lot of necrosis is present) and reconstruction of the
soft tissue envelope [121].ﬁcient fracture reductiona
e, which does not allow sufﬁcient wound closure
lcoholism, diabetes, vascular insufﬁciency, smoking)
erative pathogen identiﬁcation often not possible (like
sen and microbiology analysis detect postoperatively a
trongly be considered.
ter fracture ﬁxation: Current surgical and microbiological concepts,
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CT, MRI and nuclear imaging modalities are helpful to plan the
resection margins including safety zones. The operating surgeon
should be aware that resection lines should be re-evaluated during
surgery, since transition from necrotic to vital bone is not always
obvious from preoperative imaging. Necrotic, non-bleeding bone is
removed with a chisel or high-speed burr and represents one of the
most critical steps in surgery. Intramedullary infection manifes-
tations require debridement of the intramedullary canal using a
classic reamer or a Reamer  Irrigator  Aspirator (RIA,
DepuySynthes; Johnson & Johnson Co. Inc., New Brunswick, NJ,
USA) system [121,122].
If possible, stability of the bone should be preserved, although
in certain cases where extensive debridement leads to instability,
especially when fracture consolidation did not take place, external
ﬁxation and later reconstruction are necessary. External ﬁxation
can be a temporary or even deﬁnitive solution (i.e. bone transport).
As mentioned before, the use of spacers can be important in these
cases, not only for dead-space management but also for local
antibiotic therapy.
Non-union lacking clinical signs of infection
In this section it will not be our goal to discuss the treatment of
non-union in general. It seems appropriate although to start with
an issue similar to the one we described for IAFF, namely that the
deﬁnition of non-union is still arbitrary [123]. It has to be stated
that recent literature starts to accept the US Food and Drug
Administration (FDA) guidelines, which deﬁnes non-union as a
fractured bone that has not completely healed within 9 months of
injury and that has not shown progression toward healing over the
past 3 consecutive months on serial radiographs [124].
Infected non-union is an underestimated problem. Gille et al.
examined culture negative samples of 23 patients with non-union
and reported the presence of bacterial RNA following analysis with
PCR in two patients (8.7%) [125]. Palmer et al. analyzed 34 samples
obtained from patients with non-union [126]. Although eight
samples had a positive conventional culture, only four of 34 cases
were negative following analysis of bacterial DNA using a
combination of Ibis molecular diagnostics and ﬂuorescence in
situ hybridization techniques. The beneﬁt of utilizing molecular
based techniques could be very important, as distinguishing
between septic and aseptic non-union is essential for determining
the course of treatment [127]. In case of a longstanding therapy-
resistant non-union, an infection should be suspected. If cultures
are negative in these patients, as mentioned earlier, PCR could be a
future solution.
The problem with this type of infection is that the diagnosis
often follows the surgical intervention. It is clear that if there is a
suspicion during surgery, an extensive surgical debridement
should be performed, as for the previously mentioned late-onset
infections. Planning a second stage procedure with removal of all
internal ﬁxation material (for sonication) and awaiting the results
from cultures, should be considered. Furthermore, the use of
spacers with local antibiotics (i.e. PMMA) is often a good additive
treatment if there is a suspicion of infection during surgery. Solely
exchanging the implant doesn’t have good results in cases of
infection as was recently described by Tsang et al. for infected non-
union of the tibia [128].Table 5
Considerations when treating infected non-union.
1. Think about infection when treating a non-union (cultures)
2. Perform a good debridement of the non-union area
3. Implant exchange is not always enough and other fracture ﬁxation methods shoul
4. When in doubt perform a planned second, deﬁnitive, procedure
Please cite this article in press as: W.J. Metsemakers, et al., Infection af
Injury (2016), http://dx.doi.org/10.1016/j.injury.2016.09.019In a second stage, when the infection has been treated, bone
grafting (i.e. Masquelet or induced-membrane technique) could for
example be considered. In case of a Masquelet procedure, the
surgeon should be sure that there is no remaining infection, as a
recent experimental study by Seebach et al. showed this can be
worsened by the introduction of mesenchymal stromal stem cells
[129]. Of course, deﬁnitive treatment with external ﬁxation (i.e.
bone transport) can also be considered [128].
Table 5 summarizes the considerations a surgeon should make
when treating an infected non-union.
Future directives
Infection complicates a signiﬁcant minority of patients after
osteosynthesis, and so improvements in both prevention and
treatment will be required to achieve better patient care in the
coming decades. Such improvements may range from better-
deﬁned and controlled peri-operative antibiotic prophylaxis, to
more rapid and speciﬁc diagnostics of even sub-acute infection, to
increased availability of antimicrobial functionalized medical
devices or bone void ﬁllers and graft material.
Preclinical studies occupy an important junction in the
assessment of such novel interventions, as this is the stage where
new or improved interventions are assessed in a controlled
environment prior to patient trials and full clinical implementation
[130,131]. Numerous in vivo models of infection have been
described in the literature, however, those that model the clinical
situation as closely as possible are considered to provide the most
robust evaluation of efﬁcacy [132]. In the case of infection after
osteosynthesis, models that incorporate bone infection associated
with a functioning implant (i.e. actually ﬁxing a surgically induced
fracture/osteotomy) achieve this goal [29].
Research and development has focused more on preventative
rather than treatment strategies, as preventative strategies are
considered more likely to have greater overall impact on health-
care costs and patient outcomes. New approaches to improve
prevention of infection after osteosynthesis have primarily focused
on local delivery of antibacterial compounds from specialized
biomaterials formulated as coatings on devices [14,16] or as
additives in bone void ﬁllers such as bone cement [133] or
bacteriostatic bone substitute materials [134].
Currently, there is to our knowledge, only one antibiotic coated
trauma implant that was available on the market, which has been
found to effectively prevent infection in even complicated cases
with high risk of infection [14,16]. In future, more antibacterial
functionalized implants are likely to come to market, offering
competing, though ultimately quite similar technologies (release
of conventional antibiotics or silver). Development and clinical
implementation of antimicrobial devices in trauma surgery is both
a scientiﬁc and economic challenge due to the complexities of the
cost beneﬁt equation for clinical studies and subsequent clinical
uptake. For this reason, in the future, good cost analyses are
necessary to further emphasize the problem of IAFF.
Looking further ahead to a scenario where antibiotic resistance
in commonly encountered pathogens may increase, antibiotic
loaded devices may become contraindicated, at least in hospitals
with high endemic rates of pathogens resistant to the antibiotics
within the implants. In this regard, silver has maintained itsd be considered (i.e. external ﬁxation)
ter fracture ﬁxation: Current surgical and microbiological concepts,
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resistance rates in clinical isolates. Antimicrobial peptides (AMP’s)
are also emerging as possible antimicrobials that do not induce
resistance within pathogens after exposure [135]. At the present
time, AMPs have been limited to topical applications, though
research strategies for implant functionalization have continued to
emerge [136], and may yet prove a critical support in the face of
antibiotic resistance.
Finally, hydrogels have recently emerged as promising vehicles
for antibiotic delivery into trauma wounds [88]. Recently, early
phase clinical studies have been described whereby antibiotic
loaded hydrogels have been applied to patients during osteosyn-
thesis [137]. These hydrogels offer the beneﬁt of ease of application
to potentially complex wounds and may cover both the implant
surface and the surrounding tissues. Coatings or bone void ﬁllers,
in contrast, may leach antibiotics from the surface to the
surrounding tissues, but the surgical ﬁeld may extend signiﬁcantly
beyond the peri-implant space. Hydrogels, on the other hand, can
be applied through the wound site due to their viscous yet ﬂowing
nature [138]. It remains to be seen if such hydrogels progress to
routine clinical implementation, but at the current time, they offer
an attractive option for antibacterial delivery to trauma wounds.
Summary
One of the most challenging complications in trauma surgery is
the development of IAFF. The consequences for patients and
healthcare systems regarding this complication are severe. Despite
modern advances, implant-related infection remains a problem in
fracture care. This article gives an overview of current standpoints
regarding diagnosis and treatment of this serious complication.
Further clinical and translational research is necessary to improve
the outcome of this speciﬁc patient population.
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